TRINETRA › Sectors › Healthcare
Dr. Agarwal's Health Care Limited (AGARWALEYE) — share price, P/E and fundamentals
Dr. Agarwal's Health Care Limited (NSE: AGARWALEYE) closed at ₹509.20 on 30 Oct 2026, -6.7% over one year, against a 52-week range of ₹401.00 – ₹567.75.
In the quarter ended 30 Jun 2026 (consolidated, filed 4 Aug 2026) it reported revenue of ₹614 cr and net profit of ₹45 cr, a 7.4% net margin; revenue grew 26.0% and profit grew 40.2% year on year.
On four consecutive filed quarters its trailing P/E is 108.8; since 18 Aug 2025 its own P/E has ranged from 97.6 to 194.9 (median 114.2), and today's reading is higher than 23% of those 295 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 8.9%, ROCE 11.3%, debt-to-equity 0.08, Piotroski F-score 8 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 17% of 64 sector peers; PBT margin higher than 23% of 64 sector peers; ROE higher than 19% of 64 sector peers.
Key figures
| Last close | ₹509.20 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +1.4% / +16.2% / -6.7% |
| 52-week low – high | ₹401.00 – ₹567.75 |
| Market capitalisation | ₹16,142 cr |
| Trailing P/E | 108.8 |
| Price / book | 7.97 |
| EV / EBITDA | 24.9 |
| Earnings yield | 0.9% |
| TTM EPS | ₹4.68 |
| TTM net profit | ₹148 cr |
| Quarter revenue | ₹614 cr |
| Quarter net profit | ₹45 cr |
| Net margin | 7.4% |
| Revenue growth (YoY) | +26.0% |
| Profit growth (YoY) | +40.2% |
| Return on equity | 8.9% |
| ROCE | 11.3% |
| Debt / equity | 0.08 |
| Current ratio | 1.24 |
| Free cash flow | ₹71 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹12.2 cr |
Against Healthcare peers
| Metric | AGARWALEYE | Peer median | Percentile |
|---|---|---|---|
| Net margin | 7.37 | 12.89 | 17 |
| PBT margin | 12.24 | 17.68 | 23 |
| ROE | 8.93 | 13.87 | 19 |
| ROCE | 11.32 | 17.26 | 20 |
| Debt / equity | 0.08 | 0.11 | 45 |
| Cash conversion | 3.09 | 1.25 | 94 |
| Trailing P/E | 108.79 | 43.26 | 93 |
| P/B | 7.97 | 6.02 | 71 |
Questions
What is the P/E ratio of Dr. Agarwal's Health Care Limited?
Dr. Agarwal's Health Care Limited's trailing P/E is 108.8, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 18 Aug 2025 its P/E has ranged 97.6–194.9.
What were Dr. Agarwal's Health Care Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Dr. Agarwal's Health Care Limited reported revenue of ₹614 cr and net profit of ₹45 cr (consolidated), filed with the exchange on 4 Aug 2026.
What is Dr. Agarwal's Health Care Limited's ROE?
Return on equity is 8.9% based on the balance sheet dated 31 Mar 2026.
Does Dr. Agarwal's Health Care Limited have debt?
Debt-to-equity is 0.08 on the balance sheet dated 31 Mar 2026.
What is AGARWALEYE's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, AGARWALEYE traded between ₹401.00 and ₹567.75.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.